Evidence map›Paper›PMID 35570493›Full record

Trial reportJournal of Alzheimer's disease : JAD2022

Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.

Daisuke Asaoka, Jinzhong Xiao, Tsutomu Takeda, Naotake Yanagisawa, Takahiro Yamazaki, Yoichiro Matsubara, Hideki Sugiyama, Noemi Endo, Motoyuki Higa, Koji Kasanuki and 9 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Nutrients · 2025
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Efficacy and Safety ofNutrients · 2025
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Daisuke AsaokaDepartment of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.
Jinzhong XiaoDepartment of Microbiota Research, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tsutomu TakedaDepartment of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.
Naotake YanagisawaMedical Technology Innovation Center, Juntendo University, Tokyo, Japan.
Takahiro YamazakiDepartment of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Yoichiro MatsubaraDepartment of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Hideki SugiyamaDepartment of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Noemi EndoDepartment of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Motoyuki HigaDepartment of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Koji KasanukiDepartment of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Yosuke IchimiyaDepartment of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Shigeo KoidoDepartment of Gastroenterology and Hepatology, The Jikei University Kashiwa Hospital, Kashiwa, Japan.
Kazuya OhnoNext Generation Science Institute, Morinaga Milk Industry Co., Ltd., Zama, Japan.
Francois BernierNext Generation Science Institute, Morinaga Milk Industry Co., Ltd., Zama, Japan.
Noriko KatsumataDepartment of Microbiota Research, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Akihito NagaharaDepartment of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
Heii AraiALZCLINIC TOKYO, Chiyoda-ku, Tokyo.
Toshifumi OhkusaDepartment of Microbiota Research, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Nobuhiro SatoDepartment of Microbiota Research, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProbiotics have been reported to ameliorate cognitive impairment.

objectiveWe investigated the effect of the probiotic strain Bifidobacterium breve MCC1274 (A1) in enhancing cognition and preventing brain atrophy of older patients with mild cognitive impairment (MCI).

methodsIn this RCT, 130 patients aged from 65 to 88 years old with suspected MCI received once daily either probiotic (B. breve MCC1274, 2×1010 CFU) or placebo for 24 weeks. Cognitive functions were assessed by ADAS-Jcog and MMSE tests. Participants underwent MRI to determine brain atrophy changes using Voxel-based Specific Regional Analysis System for Alzheimer's disease (VSRAD). Fecal samples were collected for the analysis of gut microbiota composition.

resultsAnalysis was performed on 115 participants as the full analysis set (probiotic 55, placebo 60). ADAS-Jcog subscale "orientation" was significantly improved compared to placebo at 24 weeks. MMSE subscales "orientation in time" and "writing" were significantly improved compared to placebo in the lower baseline MMSE (< 25) subgroup at 24 weeks. VSRAD scores worsened in the placebo group; probiotic supplementation tended to suppress the progression, in particular among those subjects with progressed brain atrophy (VOI Z-score ≥1.0). There were no marked changes in the overall composition of the gut microbiota by the probiotic supplementation.

conclusionImprovement of cognitive function was observed on some subscales scores only likely due to the lower sensitiveness of these tests for MCI subjects. Probiotics consumption for 24 weeks suppressed brain atrophy progression, suggesting that B. breve MCC1274 helps prevent cognitive impairment of MCI subjects.

Indexed as

Bifidobacterium breveCognitive DysfunctionProbioticsAgedAged, 80 and overAtrophyBrainCognitionDouble-Blind MethodHumansBifidobacteriumbrain atrophycognitive functionmild cognitive impairmentprobiotics

Identifiers

PMID35570493
PMCPMC9277669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.